Who Generates Higher Gross Profit? Regeneron Pharmaceuticals, Inc. or Perrigo Company plc

Regeneron vs. Perrigo: A Decade of Gross Profit Dominance

__timestampPerrigo Company plcRegeneron Pharmaceuticals, Inc.
Wednesday, January 1, 201414477000002614539000
Thursday, January 1, 201517124000003711019000
Friday, January 1, 201620518000004560733000
Sunday, January 1, 201719795000005475166000
Monday, January 1, 201818315000006276700000
Tuesday, January 1, 201917733000007081200000
Wednesday, January 1, 202018152000007377200000
Friday, January 1, 2021141620000013634200000
Saturday, January 1, 2022145540000010612500000
Sunday, January 1, 2023168040000011301400000
Monday, January 1, 202412231500000
Loading chart...

In pursuit of knowledge

A Tale of Two Companies: Gross Profit Showdown

In the competitive world of pharmaceuticals, financial performance is a key indicator of success. Over the past decade, Regeneron Pharmaceuticals, Inc. has consistently outperformed Perrigo Company plc in terms of gross profit. From 2014 to 2023, Regeneron's gross profit surged by approximately 332%, peaking at over $13 billion in 2021. In contrast, Perrigo's growth was more modest, with a 16% increase, reaching its highest gross profit of around $2 billion in 2016.

The Growth Trajectory

Regeneron's impressive growth trajectory can be attributed to its innovative product pipeline and strategic market positioning. Meanwhile, Perrigo's steady performance reflects its focus on consumer healthcare products. As of 2023, Regeneron's gross profit remains nearly seven times higher than Perrigo's, highlighting its dominant position in the industry. This financial disparity underscores the importance of innovation and strategic foresight in achieving long-term success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025